MedTrace Logo

The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19

NCT05619640 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-11-22

No results posted yet for this study

Summary

COVID-19 causes a wide spectrum of clinical illness, from upper respiratory symptoms to severe respiratory failure and death. Several plasma biomarkers -such as IL-6, C-reactive protein (CRP), D-dimer, the neutrophil-to-lymphocyte ratio, and ferritin, among others- have been studied as markers of disease severity and prognosis. Besides, as alveolar damage biomarkers such as Surfactant protein D (SP-D), Krebs von den Lungen-6 (KL-6), and soluble Receptor for Advanced Glycation end products (sRAGE) can be used in lung diseases as well as COVID-19 pneumonia. The investigators hypothesized that serum SP-D, KL-6 and sRAGE levels increases in the setting of COVID-19 pneumonia. In this prospective study the investigators aimed to determine the clinical value of serum KL-6, SP-D and sRAGE levels as a prognostic marker in children with COVID-19 patients. In the literature review, it has been determined that there is no study conducted or published in pediatric patients for this purpose, and it is aimed that our study will be a pioneer study on this subject.

Conditions

  • Alveolar; Injury
  • Children
  • Pneumonia, Viral
  • SARS CoV 2 Infection

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    collaborator OTHER

  • Haseki Training and Research Hospital

    lead OTHER

Principal Investigators

  • Gulsen Akkoc, M.D. · Haseki Training and Research Hospital

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-06-21
Completion
2022-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05619640 on ClinicalTrials.gov